Annual CFF
$212.58 M
-$116.38 M-35.38%
31 December 2023
Summary:
Verve Therapeutics annual cash flow from financing activities is currently $212.58 million, with the most recent change of -$116.38 million (-35.38%) on 31 December 2023. During the last 3 years, it has risen by +$119.95 million (+129.50%). VERV annual CFF is now -43.63% below its all-time high of $377.09 million, reached on 31 December 2021.VERV Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$14.00 K
-$1.28 M-98.92%
30 September 2024
Summary:
Verve Therapeutics quarterly cash flow from financing activities is currently $14.00 thousand, with the most recent change of -$1.28 million (-98.92%) on 30 September 2024. Over the past year, it has dropped by -$31.91 million (-99.96%). VERV quarterly CFF is now -100.00% below its all-time high of $288.41 million, reached on 30 September 2022.VERV Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$201.43 M
-$31.91 M-13.68%
30 September 2024
Summary:
Verve Therapeutics TTM cash flow from financing activities is currently $201.43 million, with the most recent change of -$31.91 million (-13.68%) on 30 September 2024. Over the past year, it has increased by +$126.64 million (+169.32%). VERV TTM CFF is now -46.58% below its all-time high of $377.09 million, reached on 31 December 2021.VERV TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VERV Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -35.4% | -100.0% | +169.3% |
| 3 y3 years | +129.5% | +101.6% | -46.4% |
| 5 y5 years | - | - | - |
VERV Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -43.6% | +129.5% | -100.0% | +101.6% | -46.6% | >+9999.0% |
| 5 y | 5 years | -43.6% | +1084.0% | -100.0% | +101.6% | -46.6% | >+9999.0% |
| alltime | all time | -43.6% | +1084.0% | -100.0% | +101.6% | -46.6% | >+9999.0% |
Verve Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $14.00 K(-98.9%) | $201.43 M(-13.7%) |
| June 2024 | - | $1.30 M(-94.3%) | $233.34 M(+0.0%) |
| Mar 2024 | - | $22.73 M(-87.2%) | $233.27 M(+9.7%) |
| Dec 2023 | $212.58 M(-35.4%) | $177.38 M(+455.7%) | $212.58 M(+184.2%) |
| Sept 2023 | - | $31.92 M(+2489.1%) | $74.79 M(-77.4%) |
| June 2023 | - | $1.23 M(-39.5%) | $331.28 M(+0.2%) |
| Mar 2023 | - | $2.04 M(-94.9%) | $330.49 M(+0.5%) |
| Dec 2022 | $328.96 M | $39.60 M(-86.3%) | $328.96 M(+13.2%) |
| Sept 2022 | - | $288.41 M(>+9900.0%) | $290.58 M(>+9900.0%) |
| June 2022 | - | $445.00 K(-11.9%) | $1.31 M(-99.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $505.00 K(-58.7%) | $283.76 M(-24.7%) |
| Dec 2021 | $377.09 M(+307.1%) | $1.22 M(-241.2%) | $377.09 M(+0.3%) |
| Sept 2021 | - | -$867.00 K(-100.3%) | $375.87 M(-0.2%) |
| June 2021 | - | $282.90 M(+201.5%) | $376.74 M(+140.4%) |
| Mar 2021 | - | $93.83 M(>+9900.0%) | $156.73 M(+69.2%) |
| Dec 2020 | $92.63 M(+415.9%) | - | - |
| Dec 2020 | - | $8000.00(>+9900.0%) | $92.63 M(+0.0%) |
| Sept 2020 | - | $0.00(-100.0%) | $92.62 M(0.0%) |
| June 2020 | - | $62.89 M(+111.5%) | $92.62 M(+211.5%) |
| Mar 2020 | - | $29.73 M | $29.73 M |
| Dec 2019 | $17.95 M | - | - |
FAQ
- What is Verve Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Verve Therapeutics?
- What is Verve Therapeutics annual CFF year-on-year change?
- What is Verve Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Verve Therapeutics?
- What is Verve Therapeutics quarterly CFF year-on-year change?
- What is Verve Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Verve Therapeutics?
- What is Verve Therapeutics TTM CFF year-on-year change?
What is Verve Therapeutics annual cash flow from financing activities?
The current annual CFF of VERV is $212.58 M
What is the all time high annual CFF for Verve Therapeutics?
Verve Therapeutics all-time high annual cash flow from financing activities is $377.09 M
What is Verve Therapeutics annual CFF year-on-year change?
Over the past year, VERV annual cash flow from financing activities has changed by -$116.38 M (-35.38%)
What is Verve Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VERV is $14.00 K
What is the all time high quarterly CFF for Verve Therapeutics?
Verve Therapeutics all-time high quarterly cash flow from financing activities is $288.41 M
What is Verve Therapeutics quarterly CFF year-on-year change?
Over the past year, VERV quarterly cash flow from financing activities has changed by -$31.91 M (-99.96%)
What is Verve Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VERV is $201.43 M
What is the all time high TTM CFF for Verve Therapeutics?
Verve Therapeutics all-time high TTM cash flow from financing activities is $377.09 M
What is Verve Therapeutics TTM CFF year-on-year change?
Over the past year, VERV TTM cash flow from financing activities has changed by +$126.64 M (+169.32%)